IRIS
DE TURSI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.767
AS - Asia 3.677
EU - Europa 3.519
SA - Sud America 608
AF - Africa 79
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 5
Totale 13.668
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.646
SG - Singapore 1.754
CN - Cina 833
IE - Irlanda 677
IT - Italia 636
BR - Brasile 496
RU - Federazione Russa 455
SE - Svezia 436
VN - Vietnam 434
UA - Ucraina 271
DE - Germania 257
FR - Francia 233
GB - Regno Unito 231
TR - Turchia 189
IN - India 170
FI - Finlandia 80
HK - Hong Kong 77
CA - Canada 52
MX - Messico 50
BE - Belgio 46
PL - Polonia 45
JP - Giappone 41
AT - Austria 39
BD - Bangladesh 33
AR - Argentina 31
ZA - Sudafrica 30
IQ - Iraq 28
NL - Olanda 24
ES - Italia 20
CO - Colombia 19
CZ - Repubblica Ceca 19
PK - Pakistan 17
EC - Ecuador 16
EG - Egitto 13
UZ - Uzbekistan 13
ID - Indonesia 12
EU - Europa 11
MA - Marocco 11
PY - Paraguay 11
VE - Venezuela 11
LT - Lituania 10
CL - Cile 8
MY - Malesia 8
PT - Portogallo 8
JO - Giordania 7
KE - Kenya 7
PH - Filippine 7
RO - Romania 7
SA - Arabia Saudita 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
PE - Perù 6
AL - Albania 5
GR - Grecia 5
KR - Corea 5
TN - Tunisia 5
AU - Australia 4
JM - Giamaica 4
LB - Libano 4
NP - Nepal 4
AZ - Azerbaigian 3
BO - Bolivia 3
CH - Svizzera 3
DZ - Algeria 3
ET - Etiopia 3
GE - Georgia 3
GT - Guatemala 3
IL - Israele 3
OM - Oman 3
HN - Honduras 2
IR - Iran 2
MM - Myanmar 2
MN - Mongolia 2
NI - Nicaragua 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CM - Camerun 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GD - Grenada 1
HU - Ungheria 1
KW - Kuwait 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MT - Malta 1
Totale 13.660
Salva come PNG Salva come JPEG
Città #
Singapore 1.339
Chandler 877
Dublin 653
San Jose 533
Jacksonville 447
Ashburn 439
Dallas 266
Princeton 262
Beijing 244
Los Angeles 169
Ho Chi Minh City 132
The Dalles 131
Nanjing 124
Chieti 119
Santa Clara 115
Izmir 112
Dearborn 105
Wilmington 105
Southend 104
Altamura 100
Hanoi 96
New York 95
Ann Arbor 89
Munich 74
Pescara 73
Hong Kong 70
Boardman 57
Cambridge 54
Buffalo 53
Council Bluffs 52
Moscow 51
Redondo Beach 50
Dong Ket 47
Brussels 44
São Paulo 44
Washington 41
Frankfurt am Main 38
Tokyo 38
Menlo Park 36
Warsaw 33
Tongling 32
Nanchang 30
Orem 30
Houston 27
Rome 26
Montreal 25
Helsinki 24
London 24
Shenyang 24
Boston 23
Johannesburg 23
Milan 23
Nuremberg 23
Da Nang 21
Denver 21
Norwalk 21
Rio de Janeiro 21
Vienna 21
Amsterdam 20
Hefei 20
Atlanta 19
Brooklyn 19
Chicago 19
Falls Church 19
Hebei 19
Mexico City 19
Woodbridge 19
Kunming 18
Phoenix 18
Seattle 17
Chennai 16
Stockholm 16
Tianjin 16
Haiphong 15
Ancona 13
Baghdad 13
Jiaxing 13
Poplar 13
Turku 13
Hangzhou 12
Hyderabad 12
San Francisco 12
Brno 11
Dhaka 11
New Delhi 11
Porto Alegre 11
Toronto 11
Cairo 10
Edinburgh 10
Manchester 10
Pune 10
Tashkent 10
Belo Horizonte 9
Campinas 9
Charlotte 9
Guayaquil 9
Redwood City 9
Curitiba 8
Grevenbroich 8
Jakarta 8
Totale 8.514
Salva come PNG Salva come JPEG
Nome #
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 173
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 172
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 170
A multicenter phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary Results 169
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 164
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 163
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 157
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 156
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 155
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 153
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 150
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 148
PERITONECTOMIA ED HIPEC NEL TRATTAMENTO DELLA CARCINOSI PERITONEALE: RISULTATI PRELIMINARI DOPO UN ANNO DI ESPERIENZA 148
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 146
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 146
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 146
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 145
New Targets for Therapy in Pancreatic Cancer 144
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 142
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 137
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 135
PO-1074 Radiotherapy and immuno-check point inhibitors for brain metastases. A mono-institutional analysis 135
Cytokine Levels and UVr Sensitivity in HaCaT Cells and Cetuximab Treated Patients. 131
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 131
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 129
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 128
Speed rate (SR) as a new dynamic index of melanoma behavior 127
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 127
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 126
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 126
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 125
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 124
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 124
Principali effetti collaterali delle terapie mediche 122
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 122
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 122
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 121
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 120
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 119
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 119
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 119
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 116
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 116
A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results 116
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 114
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 113
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 113
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 113
Enzalutamide in patients with castration-refractory prostate cancer: Retrospective, multicenter, real life study 113
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 112
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 112
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 112
Rivaroxaban for cancer-associated cardiac thrombosis 111
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 110
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 110
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study 110
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 110
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 109
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 108
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 106
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study 106
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 106
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 105
Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study 104
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 102
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study 102
Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure 102
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 101
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors 99
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 98
Real world treatment practice in patients with advanced melanoma in the nivolumab era: five novel Italian case reports and a literature review 98
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 97
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients 95
Pretreatment neutrophil-lymphocyte ratio (NLR) predicted overall survival (OS) for metastatic melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) patients who received monotherapy with immune checkpoint inhibitor as ipilimumab, nivolumab and pembrolizumab 95
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results 94
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 92
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 92
A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC) 92
Cabazitaxel after Docetaxel in patients with metastatic, castration-resistant, prostate cancer (mCRPC): A prospective, observational study about toxicity profile and quality of life. 91
F05Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 91
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 91
PO-06 Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 91
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding study 90
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 90
null 90
Epirubicin plus low-dose trastuzumab in HER2 positivemetastatic breast cancer 89
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 89
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. 88
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 88
P1.09 Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation in NSCLC 87
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents 87
Enzalutamide in real life: Results from a retrospective, multicenter, italian study 87
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 87
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS) 86
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer 85
Treatment and outcome (s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC) 85
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. 85
Poor risk metastatic renal cell carcinoma (mRCC) patients are not a homogeneous group: a new stratificating model in the era of targeted therapy. 84
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 83
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 83
Totale 11.547
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.908
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.908
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021157 0 0 0 0 0 0 0 0 0 51 30 76
2021/2022803 19 28 14 193 75 26 20 43 51 20 68 246
2022/20232.328 205 323 188 257 166 411 115 216 273 23 103 48
2023/20241.042 63 32 79 34 67 394 177 43 25 35 10 83
2024/20252.335 133 454 303 68 56 125 120 126 256 140 290 264
2025/20264.857 409 202 564 661 544 331 879 300 574 393 0 0
Totale 14.412